Glembatumumab vedotin
- Generic Name
- Glembatumumab vedotin
- Drug Type
- Biotech
- CAS Number
- 1182215-65-1
- Unique Ingredient Identifier
- 1568H6A58U
- Background
A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
- Indication
Investigated for use/treatment in melanoma.
Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- University of Virginia
- Registration Number
- NCT03473691
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
- Conditions
- Advanced Malignant Solid NeoplasmEstrogen Receptor NegativeGPNMB PositiveHER2/Neu NegativeStage IV Breast Cancer AJCC v6 and v7Stage IV Cutaneous Melanoma AJCC v6 and v7Metastatic Malignant Solid NeoplasmProgesterone Receptor NegativeStage III Breast Cancer AJCC v7Stage III Uveal Melanoma AJCC v7
- Interventions
- Biological: IpilimumabOther: Laboratory Biomarker AnalysisBiological: NivolumabOther: Pharmacological Study
- First Posted Date
- 2017-10-31
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03326258
Individual Patient Expanded Access-Glembatumumab Vedotin
- Conditions
- Metastatic gpNMB Expressing Triple Negative Breast Cancer
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2018-05-21
- Lead Sponsor
- Celldex Therapeutics
- Registration Number
- NCT03067935
Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
- Conditions
- Recurrent Osteosarcoma
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT02487979
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
- Conditions
- Recurrent Uveal MelanomaStage IV Uveal Melanoma AJCC v7
- Interventions
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2020-08-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT02363283
- Locations
- 🇺🇸
University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
🇺🇸University of Kansas Clinical Research Center, Fairway, Kansas, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
- Conditions
- Melanoma
- Interventions
- Drug: glembatumumab vedotin and varlilumabDrug: glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)Drug: glembatumumab vedotin and CDX-301
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 132
- Registration Number
- NCT02302339
- Locations
- 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
- Conditions
- Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 327
- Registration Number
- NCT01997333
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇮🇹Fondazione Policlinico Universitario A Gemelli, Roma, Lazio, Italy
🇪🇸Hospital Regional Universitario de Malaga - Hospital General, Malaga, Málaga, Spain
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: "Investigator's Choice" chemotherapy
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 120
- Registration Number
- NCT01156753
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
Study of CR011-vcMMAE to Treat Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2008-06-24
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- CuraGen Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT00704158
- Locations
- 🇺🇸
Florida Cancer Specialists, Ft. Myers, Florida, United States
🇺🇸Hematology Oncology Associates, Lake Worth, Florida, United States
🇺🇸Georgia Cancer Specialists, Atlanta, Georgia, United States
A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
- Conditions
- Unresectable Stage III or Stage IV Melanoma
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2015-02-19
- Lead Sponsor
- CuraGen Corporation
- Target Recruit Count
- 117
- Registration Number
- NCT00412828
- Locations
- 🇺🇸
New York University Medical Center, New York, New York, United States
🇺🇸Angeles Clinic and Research Institute, Santa Monica, California, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.